{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-007386","form_type":"8-K","ticker":"AGPU","cik":"0001446159","company_name":"Axe Compute Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.693661+00:00","generated_at":"2026-06-21T22:42:14.165434+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Predictive Oncology Q3 revenue $455.8K (+45% YoY); appoints new CEO Raymond Vennare","bullets":["Q3 revenue $455,827, up 45% from $313,663 in Q3 2021; gross margin improved to 76% from 65%.","Net loss for nine months $17.8M vs $11.9M year ago, including $7.2M goodwill impairment for zPREDICTA.","Raymond F. Vennare appointed CEO and Chairman; he has 30+ years biotech experience.","R&D expenses down 50% to $116,763; G&A up to $3.29M due to acquisition and CEO retirement costs.","Cash and equivalents $25.4M at Sept 30, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-007386","json":"https://secwatch.observer/filing/0001171843-22-007386.json","markdown":"https://secwatch.observer/filing/0001171843-22-007386.md","text":"https://secwatch.observer/filing/0001171843-22-007386.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1446159/000117184322007386/0001171843-22-007386-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1446159/000117184322007386/f8k_111022.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T22:42:14.165434+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f75a9a7bd868c7b0e87fc16b3ea63f5ffdc4ebe7","claim":"Axe Compute Inc. reported third quarter ended September 30, 2022 results: revenue $455,827.","evidence_excerpt":"issues surrounding the therapeutic use of human tissue and cells. Q3 2022 Financial results The consolidated reportable segments of Predictive Oncology’s recognized revenue is $455,827 for the quarter, which has increased from $313,663 to the comparative three-month period of 2021, which depicts a revenue growth of 45%. Helomics reported an improvement in its","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1446159/000117184322007386/0001171843-22-007386-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$455,827"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}